T-1201 (DBPR115) Technique transfer from National Health Research Institute (NHRI)
Taivex Therapeutics Corporation (Taivex) and The National Health Research Institutes (NHRI) are pleased to announce the technology transfer of T-1201 (formerly, DBPR115), a potential anti-cancer developmental drug candidate, effective on Augest 18, 2016.This targeting drug, T-1201 could deliver the itself to the tumor site and make the drug accumulated at the tumor site. Increasing the …
T-1201 (DBPR115) Technique transfer from National Health Research Institute (NHRI) Read More »